Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for patients suffering from complex rare diseases using the company's novel cell penetrating peptide (CPP) technology platform.
The company's lead p…
Analysis
Larimar Therapeutics's 360° View rank of 26 places it below its peer average — better than 26% of its true peers.
It's lagging on growth (21) and reasonably valued (72). On safety it is carrying more balance-sheet risk (36), and the market shows skeptical sentiment (17). Taken together, its Combined rank of 40 reads as below its peer average.
360° rank · history
1007550250
Jun 202626
26
2026
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
37
—
—
—
Price/Earnings
29
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
72
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.